24-Apr-2026
TipRanks (Thu, 23-Apr 7:21 AM ET)
Zymeworks (ZYME) Gets a Buy from Stifel Nicolaus
TipRanks (Wed, 22-Apr 8:00 AM ET)
Globe Newswire (Tue, 21-Apr 5:30 PM ET)
Globe Newswire (Fri, 17-Apr 3:00 PM ET)
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
Globe Newswire (Thu, 16-Apr 6:00 AM ET)
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
Globe Newswire (Thu, 9-Apr 6:00 AM ET)
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
Globe Newswire (Wed, 1-Apr 6:00 AM ET)
Market Chameleon (Mon, 30-Mar 3:53 AM ET)
Globe Newswire (Mon, 30-Mar 6:00 AM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 24-Mar 6:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of April 24, 2026, ZYME stock price climbed to $28.10 with 484,477 million shares trading.
ZYME has a beta of 0.60, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.02 to the broad based SPY ETF.
ZYME has a market cap of $2.09 billion. This is considered a Mid Cap stock.
Last quarter Zymeworks reported $3 million in Revenue and -$.55 earnings per share. This fell short of revenue expectation by $-18 million and missed earnings estimates by -$.22.
In the last 3 years, ZYME traded as high as $28.88 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a price return of +124.4% while the SPY ETF gained +31.9%. ZYME has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.9% and +6.8%, respectively, while the SPY returned +3.8% and +5.1%, respectively.
ZYME support price is $26.71 and resistance is $28.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.